Elahere (mirvetuximab soravtansine) meets primary end point of PICCOLO trial in FR alpha-High, platinum-sensitive ovarian cancer – AbbVie
AbbVie announced positive topline results from the Phase II PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRalpha) positive, platinum-sensitive ovarian… read more.
